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ABSTRACT 
Purpose: This study aims to evaluate the effectiveness of intralesional bleomycin sclerotherapy in the treatment of 
lymphangioma in children and to determine the incidence of complications in the treatment.  
Methods: This is a retrospective study of 24 children diagnosed with lymphangioma and treated with intralesional 
injection of bleomycin aqueous solution from January 1999 to December 2004. 
Results: Complete resolution was seen in 63% (15/24) of lesions, 21% (5/24) had good response and 16% (4/24) 
had poor response. The tumour recurred in 2 patients. Two other patients had abscess formation at the site of injection. 
No other serious complications or side effects were observed.  
Conclusion: Intralesional bleomycin therapy was very effective in the treatment of lymphangioma. Our results 
were comparable to other published studies. Bleomycin administered as intralesional injection was found to be safe as 
there was no serious complication or side effect observed in this study. © 2011 Biomedical Imaging and Intervention 
Journal. All rights reserved. 
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INTRODUCTION 
Lymphangioma is a benign slow growing tumour of 
lymphatic vessels. It may arise in any organ or soft tissue. 
The most frequent occurrence is in the head and neck 
region and involves the axilla and mediastinum. This 
tumour is mainly confined to the paediatric age group, 
but occurrences have been reported in adults. It manifests 
at birth in up to 65% and presents by the age of 2 years 
in 80–90% of cases [1]. The incidence of lymphangioma 
is reported to be from 1.5–2.8 per 1000, and it has no 
predilection for either sex or any race. The most common 
symptoms are swelling and cosmetic deformity. A large 
lesion in the neck can compress vital structures, cause 
respiratory obstruction, dysphagia and symptoms of 
nerve compression.  
Intralesional sclerotherapy has become an 
acceptable method of treatment for lymphangiomas in 
children. It involves the use of a sclerosing agent that 
causes irritation of the endothelial lining of the 
lymphangioma, which leads to inflammation, fibrosis 
and involution [2]. Other modes of treatment such as 
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surgical resection, incision and drainage, and radiation 
therapy have produced unsatisfactory results. Surgical 
resection for complete removal in many cases is 
impossible due to the nature of the lesion, which has a 
propensity to infiltrate tissue planes and encircle 
important neurovascular structures. Tumour recurrences 
and nerve injuries are common complications following 
surgery. 
Previously reserved for treatment of unresectable 
lymphangiomas or in cases of tumour recurrence 
following surgery, intralesional sclerotherapy has gained 
popularity over recent years. Several studies using 
bleomycin and a newer agent OK-432 as sclerosants, 
have shown that this method of treatment produces 
favourable results compared to surgery.  
We have been using bleomycin for many years, and 
the primary reason for choosing to use bleomycin is 
because it was readily available while OK432 was not 
yet available in Malaysia then. Our initial experience 
with 11 children with neck lymphangioma indicated that 
the drug was very effective [3]. This has led to a review 
of a larger series that involved childhood lymphangioma 
not just at the neck but also at other areas of the body.  
METHODS 
This was a retrospective review of 24 successive 
cases of lymphangioma referred for percutaneous 
intralesional bleomycin sclerotherapy. The procedures 
were conducted in the Radiology Departments of two 
tertiary centres in Kuala Lumpur between January 1999 
and December 2004. 
The diagnosis of lymphangioma in these patients 
was made on the basis of clinical examination and 
imaging findings [4], mainly ultrasound (USG) and 
computed tomography (CT), and in some cases magnetic 
resonance imaging (MRI). Ultrasonographic assessment 
was performed on all patients.  
Ultrasound was used mainly to confirm the 
diagnosis and to classify the type of lymphangioma. The 
tumours were classified based on the ultrasonographic 
appearance into three different subtypes: macrocystic, 
mixed and microcystic lymphangiomas (Figure 1–3). 
Patients with predominantly microcystic type of 
lymphangioma where the cysts were less than 1 cm in 
diameter were excluded from sclerotherapy. Colour 
Doppler was used to confirm absence of flow. As this 
was a review of cases performed at two centres, the 
ultrasound machines and transducers used were variable. 
Either a 5 or 7.5 MHz linear or convex probe was used. 
CT or MRI was performed to ensure that the lesion 
was not a haemangioma, which is known to produce 
negative Doppler flow but will be enhanced on CT and 
MRI. The other role was to visualise the extent of a 
lesion that had involved the parapharyngeal space and 
mediastinum. The choice of CT or MRI depended on 
availability. The authors preferred CT because it is fast 
and could be done with sedation. MRI has the advantage 
of not using ionising radiation but the long procedure 
required general anaesthesia in the younger children. In 
some cases the choice of doing CT or MRI was made by 
the referring doctor and not by the authors. 
 
 
Figure 1 Macrocystic lymphangioma that is completely cystic 
(arrows).  
 
 
Figure 2 Mixed type of lymphangioma with cysts (white arrows) 
and echogenic areas representing microcysts (black 
arrows).  
 
 
Figure 3 Microcystic lymphangioma that is echogenic (arrows). 
The echogenic appearance of the mass is due to multiple 
interfaces from the walls of tiny cysts. 
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Figure 4 Intralesional bleomycin therapy. (A) Ultrasound 
assessment before injection. (B) Aspiration of cyst 
content reveals clear serous fluid (arrow). (C) 
Ultrasound image showing the tip of aspirating needle 
(arrow) within the cyst, and (D), while keeping the tip 
of the needle within the cyst, bleomycin aqueous 
solution is administered. 
 
Patients’ age, sex, ethnicity, body weight, symptoms, 
lesion location and lesion size were recorded. Informed 
consent for intralesional bleomycin therapy was obtained 
from the guardian. 
Under the effect of sedation (oral chloral hydrate 
with IV pethidine added when necessary) and local 
anaesthetic and with strict aseptic precaution, the cystic 
components of the tumour were aspirated with a 
hypodermic syringe and 23G needle using 
ultrasonographic guidance. While keeping the tip of 
aspiration needle within a cyst lumen, 0.5  mg per kg 
body weight of bleomycin aqueous solution (1.5 mg/ml 
water) was injected (Figure 4). When more than one cyst 
was aspirated, the calculated dose was divided by the 
number of cysts aspirated and the divided dose was 
injected into each cyst [3]. This procedure was repeated 
after 4 weeks if the cystic component persisted and 
measured at least 1  cm in diameter. The maximum 
cumulative dose of bleomycin allowed was 5  mg/kg 
body weight. The same paediatric radiologist at the two 
centres conducted the procedures. 
Patients who failed sedation were re-scheduled for 
sclerotherapy under general anaesthesia (GA). 
Sclerotherapy for patients with stridor or respiratory 
distress were performed under GA. 
Patients who had lesions extending into the anterior-
superior mediastinum had bleomycin injection into the 
neck and axilla components only. 
Patients were admitted for at least 24 hours 
following the procedure and monitored for possible 
immediate and delayed complications of the treatment. 
After discharge, patients were followed-up after 2 to 4 
weeks when clinical assessment and measurements were 
made. If the lesion was still present, it was assessed with 
USG to see if further intralesional bleomycin was 
feasible. A repeat procedure was done when there were 
cysts that measured at least 1 cm in diameter. This was 
the minimum cyst size where the radiologists felt 
confident to aspirate and maintain tip of the needle 
within the cyst lumen for the bleomycin injection. 
Follow-up and additional injections were given until 
the lesion completely resolved or intralesional bleomycin 
was no longer feasible (cysts measured less than 1 cm). 
The response was graded as complete resolution (total 
disappearance), good response (showing >  50% 
reduction in size) and poor response (showing <  50% 
reduction or no change in size). Recurrence was defined 
as reappearance of the tumour after complete resolution 
or increase in size after initial significant reduction in 
size. In one centre, photographs were taken at follow-up 
for ease of comparison. When bleomycin sclerotherapy 
was no longer required or no longer feasible, the follow-
up period was increased to 3 monthly, then 6 monthly 
until the size of the lesion was stable, and then yearly [3].  
Patients who showed poor response were offered 
surgery or sclerotherapy with OK432 when it became 
available in Malaysia. 
RESULTS 
The 24 patients were aged between 1 day and 12 
years. All patients had a swelling (n  =  24). Other 
symptoms included stridor (n = 3), difficulty in breathing 
(n  =  2), difficulty in swallowing (n  =  1), pain (n  =  2), 
tenderness (n = 1), and skin erythema (n = 1) (Table 1). 
The most common site of lesion was the neck (n = 13), 
followed by face (n  =  5), axilla (n  =  5), chest (n  =  4), 
mediastinum (n  =  4), buttock (n  =  1) and thigh (n  =  1) 
(Table 1). Lesions of the face were sited over the pre- 
and post-auricular regions. Chest lesions were sited at the 
sub-clavicular region. Mediastinal extensions were only 
into the anterio-superior mediastinum. The number of 
procedures per patient varied from once to 6 times, with 
a cumulative dose of 1 to 20 mg bleomycin (Table 2). 
Total follow-up period from the time of 1
st injection 
ranged from 2 to 42 months (Table 2). 
 
 
Figure 5 (A) A 2-year-old girl (Case 10) with left supraclavicular 
lymphangioma (arrows) which had been present for 1 
year. This patient’s ultrasound is shown in Figure 1. (B) 
Complete regression. An excellent result is achieved 1 
year later, after 3 injections of bleomycin. Rozman et al. Biomed Imaging Interv J 2011; 7(3):e18   4 
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Figure 6 (A) A large disfiguring lymphangioma over the angle of 
left mandible (arrows) in a 3-month-old baby (Case 9). 
This patient’s ultrasound image is shown in Figure 2. 
(B) One year later, the appearance after three injections 
of bleomycin, significant reduction in size was 
observed. A small swelling (arrows) was noticeable in 
the pre- and post-auricular area. 
 
 
Figure 7 Poor response. This patient’s ultrasound is shown in 
Figure 3. This baby with a massive neck mass had 
respiratory distress at birth (Case 21). She was 
intubated and monitored in the intensive care unit. 
Imaging studies confirmed the swelling as 
predominantly microcystic type of lymphangioma. The 
lesion failed to regress after 6 injections of bleomycin. 
 
Complete resolution (Figure  5) was seen in 63% 
(15/24) of lesions, 20% (5/24) had good response 
(Figure  6) and the remaining 17% (4/24) had poor 
response (Figure 7). The observations were recorded at 
the end of follow-up or at the time the patient was last 
seen in the clinic, as documented in the case notes 
(Table 2). 
Intralesional bleomycin therapy failed in 4 patients 
(Table  2). The first patient who failed sclerotherapy 
(Case 17) had six injections and minimal reduction in 
size was achieved. Further, sclerotherapy could not be 
performed because this patient had mixed type of 
lymphangioma. After six injections, there were no 
further cysts large enough for aspiration and injection. 
This patient subsequently underwent surgical resection 
and 80% of the tumour mass was removed. The second 
patient who responded poorly (Case 19) had a 
predominantly microcystic type of lymphangioma and 
only one cyst was aspirated and injected. Subsequently, 
this patient underwent three intralesional OK-432 
injections. This drug therapy had also failed to reduce the 
size of the lesion and the patient underwent surgical 
resection. The third patient was a newborn who 
presented with a huge neck mass and had respiratory 
distress during postnatal period (Case 21). She was 
intubated and monitored in the Intensive Care Unit. After 
five  injections of bleomycin, there was only a slight 
reduction in the size of the mass that was predominantly 
microcystic. However, the patient became well enough to 
be extubated and went home. The fourth subject had a 
swelling in the right neck at birth (Case 23). Surgical 
excision was performed at the age of 1 month. The 
patient presented later, at the age of 12 years with a 
recurrent swelling measuring 8  ×  8  cm. Intralesional 
bleomycin was given only once, as in the subsequent 
follow-up, the remaining lesion was the microcystic 
component and was not suitable for further bleomycin 
treatment. Further surgical excision was contemplated 
but the patient defaulted follow-up. 
There were 2 (8%) recurrences. Both patients 
(Cases  1 and 4) had good response (>  50% reduction) 
after one injection of bleomycin. Both defaulted follow-
up and presented 1 year later with a swelling that was 
bigger than initial post-injection size. Case 1 had good 
response after another injection of bleomycin. The lesion 
in Case 4 completely resolved after another injection of 
bleomycin. 
Comparing the response rate with the lesion type, 10 
out of 11 macrocystic lesions had complete resolution 
and only one had a good partial response. Complete 
resolution was seen in 5 of 10 mixed lesions. The other 4 
mixed lesions had good partial response and the 
remaining 1 had poor response. All 3 predominantly 
microcystic type responded poorly to the treatment 
(Table 3). 
Immediate complications reported include skin 
erythema at injection site, local swelling, mild tenderness 
and fever, which were controlled by oral antipyretics. 
One patient had excessive vomiting from the effect of IV 
sedation. However, no life- threatening complications 
such as respiratory obstruction and severe 
hypersensitivity reaction to bleomycin were observed. 
Two patients, Cases 7 and 18 (Table 2), developed an 
abscess at the site of injection, 7 months and 1 month 
respectively after the last injection. Fistula formation and 
signs related to peripheral nerve damage were not 
observed. No patient developed excessive scarring as a 
result of the procedure. 
DISCUSSION 
The idea of using sclerotherapy in the treatment of 
lymphangioma occurred when it was noted that 
lymphatic malformations spontaneously involute when 
they became infected and the infection resolved. The first 
case of lymphangioma treated by sclerotherapy was 
reported in 1933, using sodium morrhuate. Complete 
tumour regression was noted in 6 weeks following 
intralesional injection [1]. Since then various sclerosing 
agents have been used, namely iodine, ethanolamine 
oleate, alcohol, ethibloc, tetracycline and 
cyclophosphamide. Bleomycin and OK-432 are currently Rozman et al. Biomed Imaging Interv J 2011; 7(3):e18   5 
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Table 1 Clinical data  
 
Case 
No. 
Age at diagnosis, Sex, Ethnicity, 
body weight at diagnosis (kg)  Symptoms  Lesion location, size (cm)  Lesion 
type 
1  2 y, F, Ma, 14 kg  swelling  chest, axilla, 5 × 4 × 4  mixed 
2  1 y, M, C, 8 kg  swelling  axilla, 6 × 6 × 2.5  macro 
3  11 y, F, Ma, 32 kg  swelling, pain  face, 3 × 2 × 2  macro 
4  1 y, F, Ma, 10 kg  swelling, pain, difficulty 
swallowing  neck, mediastinum, 10 × 4 × 6.5  mixed 
5  8 mo, M, Ma, 9 kg  swelling  face, 3 × 3 × 2.5  mixed 
6  6 mo, F, C, 8 kg  swelling  face, 5 × 4 × 4  macro 
7  6 mo, M, Ma, 10 kg  swelling  neck, 4 × 2 × 2.5  mixed 
8  2 y, M, C, 10 kg  swelling  chest, 6 × 4 × 4.5  macro 
9  3 mo, M, Ma, 6 kg  swelling  face, 8 × 7 × 7  mixed 
10  1 y 9 mo, F, I, 12 kg  swelling  neck, 3 × 3 × 2.5  macro 
11  1 y 8 mo, M, Ma, 9 kg  swelling, tender  buttock, 5 × 5 × 4.5  mixed 
12  5 y, F, I, 19 kg  swelling  chest, axilla, 10 × 8 × 8.5  macro 
13  8 mo, F, Ma, 12 kg  swelling  neck, 3 × 2 × 2  macro 
14  2 y, M, Ma, 9 kg  swelling, skin erythema  neck, face, 12 × 10 × 10.5  mixed 
15  4 d, F, Ma, 7 kg  swelling  neck, 8 × 6 × 6.5  macro 
16  3 y, M, Ma, 13 kg  swelling, difficulty in breathing 
during sleep  neck, 6 × 5 × 5  macro 
17  9 mo, M, C, 9 kg  swelling, positional stridor  neck, axilla, 
mediastinum,15 × 15 × 14.5 
mixed 
18  11 d, F, Ma, 3 kg  swelling, stridor  neck, chest, mediastinum, 
9 × 8 × 8  mixed 
19  1 mo, F, Ma, 4 kg  swelling, stridor  neck, mediastinum, 
12 × 10 × 10.5  micro 
20  1 y 7 mo, F, Ma, 9 kg  swelling  neck, 6 × 6 × 6  mixed 
21  1 d, F, C, 3 kg  swelling, stridor, respiratory distress  neck, 13 × 7 × 9.5  micro 
22  8 y, M, C, 28 kg  swelling  thigh, 5 × 4 × 4  macro 
23  12 y, M, Ma, 33 kg  swelling  neck, 8 × 8 × 8  micro 
24  2 y 2 mo, F, Ma, 12 kg  swelling  axilla, 9 × 10 × 9  macro 
Abbreviations y (years), mo ( months), d (days), kg (kilogram), Ma (Malay ), C (Chinese), I (Indian), macro (macrocystic), micro (microcystic) 
 
the most popular sclerosants. However, no studies have 
been conducted to compare the efficacy between these 
two agents. 
Bleomycin is an anti-neoplastic antibiotic, produced 
by the fermentation of streptomyces verticillus. 
Discovered in 1965, this drug was found to cause single- 
and double-strand DNA breaks and inhibition of DNA 
and RNA synthesis [1]. Since then it has been used for 
its anti-neoplastic property to treat malignancy. In the 
treatment of malignant pleural effusion, it was observed 
that bleomycin caused marked fibrosis and scarring. This 
sclerosing property was first put into use in the treatment 
of lymphatic malformation in 1977. In this series, 8 
patients who either had incomplete surgical resection, 
recurrent or non-resectable tumour were treated with 
bleomycin. Good results were reported in these 
patients [1]. 
Studies using bleomycin have produced promising 
results [1, 3, 5–7]. Our study indicated that intralesional 
bleomycin therapy was very effective and the results 
were comparable to these published series. Different 
authors have quoted success rates of between 36 to 63% 
for complete tumour regression, of up to 88% significant 
lesion regression, and poor response of between 12 to 
23% using either bleomycin or OK432 (Table 4). 
In line with other published data, we found that 
macrocystic and mixed type of lymphangiomas were the 
ones that responded well to the treatment. In the mixed 
and predominantly microcystic type, once the bigger 
cysts have been aspirated, leaving only small cysts and 
microscopic lymphatic channels, further aspiration could 
not be performed. This was seen in four of the mixed 
lesions. However, the lesions reduced to a size that was 
cosmetically acceptable. All our predominantly 
microcystic lesions and one mixed lesion resulted in only 
slight reduction in size following sclerotherapy. This 
small size reduction however, would facilitate surgery if 
indicated. Rozman et al. Biomed Imaging Interv J 2011; 7(3):e18   6 
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Table 2 Treatment and outcome 
 
Case 
No. 
Age at diagnosis, Sex, 
Ethnicity, body weight at 
diagnosis (kg) 
Lesion 
type 
No. of 
injections 
Total dose of 
bleomycin 
(mg) 
Sedatio
n (S) or 
GA 
Total follow-up 
period from 1
st 
injection (mo) 
Result 
1  2 y, F, Ma, 14 kg  mixed  2  17  S  2, defaulted. 2, after 
2
nd injection  Good 
2  1 y, M, C, 8 kg  macro  1  3  S  15  Resolved 
3  11 y, F, Ma, 32 kg  macro  1  15  S  4  Good 
4  1 y, F, Ma, 10 kg  mixed  2  15  GA  3, defaulted. 22, 
after 2
nd injection  Resolved 
5  8 mo, M, Ma, 9 kg  mixed  2  6  S  3  Resolved 
6  6 mo, F, C, 8 kg  macro  1  5  S  7  Resolved 
7  6 mo, M, Ma, 10 kg  mixed  1  4  S  17  Resolved 
8  2 y, M, C, 10 kg  macro  1  5  S  7  Resolved 
9  3 mo, M, Ma, 6 kg  mixed  3  8  S  12  Good 
10  1 y 9 mo, F, I, 12 kg  macro  3  17  S  7  Resolved 
11  1 y 8 mo, M, Ma, 9 kg  mixed  1  5  S  11  Resolved 
12  5 y, F, I, 19 kg  macro  2  20  S, GA  11  Resolved 
13  8 mo, F, Ma, 12 kg  macro  2  6  S  4  Resolved 
14  2 y, M, Ma, 9 kg  mixed  2  6  S  42  Resolved 
15  4 d, F, Ma, 7 kg  macro  1  3  S  2  Resolved 
16  3 y, M, Ma, 13 kg  macro  1  5  S  2  Resolved 
17  9 mo, M, C, 9 kg  mixed  6  18  S  8  Poor 
18  11 d, F, Ma, 3 kg  mixed  3  5  GA  16  Good 
19  1 mo, F, Ma, 4 kg  micro  1  1  GA  7  Poor 
20  1 y 7 mo, F, Ma, 9 kg  mixed  2  9  S  7  Good 
21  1 d, F, C, 3 kg  micro  5  8  GA  4  Poor 
22  8 y, M, C, 28 kg  macro  1  14  S  30  Resolved 
23  12 y, M, Ma, 33 kg  micro  1  17  S  5  Poor 
24  2 y 2 mo, F, Ma, 12 kg  macro  1  4  S  5  Resolved 
Abbreviations: y (years), mo ( months), d (days), kg (kilogram), Ma (Malay ), C (Chinese), I (Indian), macro (macrocystic), micro (microcystic)  
In this study, bleomycin aqueous solution was 
injected directly into a cyst after aspiration of the cyst 
content. Unlike OK-432, most authors advise against 
injecting bleomycin into the microcystic part or 
intraprenchymal component of the tumour. 
Intraparenchymal injection has higher rate of systemic 
absorption, hence, greater risk of systemic toxicity. This 
is where OK-432 has an advantage over bleomycin. 
Intraparenchymal injection of OK-432 was performed 
without significant clinical side effects. Thus, this drug 
can be used to treat microcystic lymphangioma [8–10]. 
Two recurrences of tumour were observed in this 
study. We defined recurrence as reappearance of the 
tumour after complete resolution or increase in size after 
initial significant reduction in size was seen. Both these 
patients had defaulted post-injection assessments. One 
further injection was given and one patient had complete 
resolution while the other had good response. The true 
rate of recurrences, however, could only be ascertained if 
patients were followed-up for a longer period of time. 
There were four patients with lesions that extended 
into the anterior-superior mediastinum where only the 
neck and axilla components were aspirated and injected 
with bleomycin. With this approach it was hoped that as 
the neck component reduced in size, the mediastinal 
component would retract into the neck. The mediastinal 
component were not directly aspirated and injected for 
fear that it could cause mediastinitis and compromise 
adjacent vital structures. In the 1
st reported case of 
mediastinal lymphangioma treated with percutaneous 
sclerotherapy, Ethibloc and absolute ethanol were used 
as sclerosants. In this case, the giant lymphangioma was 
located in the retrocardiac region [11].  
No serious complications were seen as a result of 
intralesional bleomycin therapy. Most patients 
complained of mild skin erythema, local swelling, 
induration, mild tenderness and fever. These symptoms 
lasted for a day or two but did not prolong their stay in 
hospital. In patients with large neck lesions and airway 
compromise was expected, support from the intensive 
care team was summoned. In these patients, intralesional Rozman et al. Biomed Imaging Interv J 2011; 7(3):e18   7 
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Table 3 Outcome of Bleomycin Sclerotherapy. 
 
Type of Lymphangioma 
Outcome  Macrocystic 
n (%) 
Mixed 
n (%) 
Microcystic 
n (%) 
Total 
n (%) 
Complete resolution  10 (42%)  5 (21%)  0  15 (63%) 
Good response 
(>50% reduction in size)  1 (4%)  4 (16%)  0  5 (20%) 
Poor response  
(<50% reduction in size)  0  1 (4%)  3 (13%)  4 (17%) 
Total  11 (46%)  10 (41%)  3 (13%)  24 (100%) 
 
 
Table 4 Results of Series using Bleomycin and OK432. 
 
Study  Year  No. of 
patients 
Significant 
regression (>50-
100% resolution) 
Complete 
Resolution 
(100% 
resolution) 
Poor/No 
Response 
(<50% 
resolution) 
Recurrence 
Bleomycin   
Rozman      2 24 4    8 84 4% %   ( (2 20 0) )    6 63 3% %   ( (1 15 5) )    1 16 6% %   ( (4 4) )    ( (2 2) )   
Mahajan [7]  2004  15  86.7% (13)  53.3% % (8)  13.3% % (2)  - -   
Zulfiqar [3]  1999  11  82% % (9)  36% % (4)  18% % (2)  - -   
Orford [6]  1995  16  88% % (14)  44% % (7)  12% % (2)  (1) 
Okada [1]  1992  29  86% % (25)  55% % (16)  14% % (4)  (3) 
Tanigawa [5]  1987  33  82% % (27)  39.4% % (13)  18% % (6)  - -   
OK-432   
Ruiz Jr. [10]  2004  19  84% % 63% % 16% %  - -   
Nielsen [9]  2003  13  77% % 46% % 23% %  - -   
Ogita [8]  1991  23  78% % 43% % 22% %  - -   
 
injection was performed under general anaesthesia with 
their airway secured. The patients remained intubated 
post-injection and monitored in the ICU for 24 hours. 
In patients with complete resolution, there was no 
undesired excessive scarring or pigmentation noted at the 
injection site. We believe that the aesthetic result from 
the use of bleomycin was as good as what was claimed 
from the use of OK-432. 
Local infections at the site of injections were seen in 
2 out of 24 patients. The abscess occurred 7 months and 
at 1 month after the last bleomycin injection. Incision 
and drainage were performed and later the 
lymphangioma resolved completely in 1 patient. Whether 
these infections occurred as a result of the sclerotherapy 
or were de-novo abscesses from the lymphangioma, 
remains unanswered. A significant time gap was 
observed between the last injection and the abscess 
formation. We, therefore, do not think that this 
complication was related to our procedure. 
The primary concern of bleomycin therapy is its risk 
of pulmonary toxicity. The risk is dose related with an 
increased incidence associated with a total dose 
exceeding 400 i.u. or a single dose exceeding 30 mg/m
2 
of body surface area given intra-venously to oncology 
patients [12]. Elderly oncology patients and those with 
underlying pulmonary disease and renal failure were at 
greater risk. However, the doses used in sclerotherapy 
were much lower than those used for oncology purposes. 
Clinical studies from Japan, India, Australia and 
Malaysia in which a total of 104 patients were treated 
with intralesional bleomycin did not report pulmonary 
fibrosis as a complication [1, 3, 5–7]. 
There was no report comparing the efficacy of the 
various sclerosing agents in a single study. Several 
published series were all review studies using a single 
agent. Double-blind, case-control clinical trials 
comparing these sclerosing agents in the treatment of 
lymphangioma would be difficult. This is due to the 
following: limited cases as there is low incidence of the 
tumour, complexity of the tumour, long follow-up after 
treatment, and the high rate of confounders that would 
contribute to biases of the obtained results. Lesion 
subtypes, its location, size and presence of complication 
could all affect the outcomes. All these confounders need 
to be controlled if statistically significant results were to 
be obtained. This would mean a very large number of Rozman et al. Biomed Imaging Interv J 2011; 7(3):e18   8 
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cases need to be recruited and would involve many 
different centres. A single series of sclerotherapy 
treatment of lymphangioma usually would not achieve 
statistically significant results. Looking at data of these 
small series together, however, may produce more 
concrete results. Solid conclusions must therefore be 
drawn from reviewing many different series as a whole. 
CONCLUSION 
Intralesional bleomycin therapy is a safe and 
effective method of treatment for lymphangioma. The 
results from our series are comparable with other 
published series. No serious side effects from 
intralesional bleomycin therapy were observed. Our 
results, together with the results from other published 
series support the continued use of sclerotherapy with 
bleomycin in the treatment of lymphangioma. 
Sclerotherapy is recommended in place of surgery as the 
first-line treatment modality. The latter must be reserved 
for those lesions where sclerotherapy had failed. Which 
sclerotherapy agent is superior? This question may only 
be answered by reviewing the results of various case 
series using the different sclerosing agents. 
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